A potent, selective and orally active cysteinyl leukotriene type 1 receptor antagonist. Used as an antiasthmatic.
相关文献及参考
[2]. Gunning WT, et al. Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201.
[3]. Lei C, et al. Zafirlukast attenuates advanced glycation end-products (AGEs)-induced degradation of articular extracellular matrix (ECM). Int Immunopharmacol. 2019;68:68-73.
Findlay, S.R., et al.: J. Allergy Clin. Immunol., 89, 1040 (1992),
Matassa, V.G., et al.: J. Med. Chem., 33, 1781 (1990),
Merck 14 ,10108
Schain, F., et al Int. J. Cancer 123 , 2285-2293, (2008)
Scuderi, N., et al Int. J. Immunopharmacol. 20 , 577-584, (2007)
Woszczek, G., et al J. Immunol. 184 , 2219-2225, (2010)
[1]. Finnerty JP, et al. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D 4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;14